SEC Form 10-Q filed by Cryo-Cell International Inc.
$CCEL
Misc Health and Biotechnology Services
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company's earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future di
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2024 were $8.07 million compared to $7.87 million for the third quarter of fiscal 2023. Net Income The Company reported net income for the three months ended August 31, 2024 of $1.05 million, or $0.13 per basic share and diluted share, compared to net income of $681,000, or $0.08 per basic and diluted share for the three months ended August 31, 2023. During the three months end
4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)
10-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
S-8 - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company's earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future di
Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2024 were $8.07 million compared to $7.87 million for the third quarter of fiscal 2023. Net Income The Company reported net income for the three months ended August 31, 2024 of $1.05 million, or $0.13 per basic share and diluted share, compared to net income of $681,000, or $0.08 per basic and diluted share for the three months ended August 31, 2023. During the three months end
MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NASDAQ:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company's Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler, M.D., who have resigned in their capacity as Directors. Mr. Gaines has chosen to retire while Dr. Wheeler has resigned for health reasons. The Board of Directors voted unanimously in favor of adding Mr. Mark Portnoy and Mr. Daniel Mizrahi as members of the Board. Mr. Portnoy is a Co-CEO of the Company and previously served as a member of the Board of Directors from 2011-2020. Mr. Miz
SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)
SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)